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Abstract
Background: Developing an effective HIV vaccine is the overriding priority for HIV prevention research.
Enrolling and maintaining cohorts of men into HIV vaccine efficacy trials is a necessary prerequisite for the
development and licensure of a safe and efficacious vaccine. Methods: One hundred-fifty consenting HIV-
negative men were enrolled into a pilot 1:1 randomised controlled trial of immediate vaccination with a three-
dose hepatitis B vaccine compared to deferred vaccination (at 12 months) to investigate feasibility and
acceptability of a future HIV vaccine trial in this population. Adverse events, changes in risk behaviour,
acceptability of trial procedures and motivations for participation in future trials were assessed. Results: Men
were a median 25 years old (inter-quartile range = 23-29), 53% were employed, 90% secondary school
educated and 67% uncircumcised. Of the 900 scheduled study visits, 90% were completed in the immediate
vaccination arm (405/450) and 88% (396/450) in the delayed arm (P = 0.338). Acceptability of trial
procedures and services was very high overall. However, only 65% of the deferred group strongly liked being
randomised compared to 90% in the immediate group (P = 0.001). Informed consent processes were viewed
favourably by 92% of the delayed and 82% of the immediate group (P = 0.080). Good quality health services,
especially if provided by a male nurse, were rated highly. Even though almost all participants had some
concern about the safety of a future HIV vaccine (98%), the majority were willing to participate in a future
trial. Future trial participation would be motivated mainly by the potential for accessing an effective vaccine
(81%) and altruism (75%), rather than by reimbursement incentives (2%). Conclusions: Recruitment and
retention of men into vaccine trials is feasible and acceptable in our setting. Findings from this surrogate
vaccine trial show a high willingness to participate in future HIV vaccine trials. While access to potentially
effective vaccines is important, quality health services are an equally compelling incentive for enrolment.
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Abstract
Background: Developing an effective HIV vaccine is the overriding priority for HIV prevention research. Enrolling
and maintaining cohorts of men into HIV vaccine efficacy trials is a necessary prerequisite for the development and
licensure of a safe and efficacious vaccine.
Methods: One hundred-fifty consenting HIV-negative men were enrolled into a pilot 1:1 randomised controlled trial
of immediate vaccination with a three-dose hepatitis B vaccine compared to deferred vaccination (at 12 months) to
investigate feasibility and acceptability of a future HIV vaccine trial in this population. Adverse events, changes in risk
behaviour, acceptability of trial procedures and motivations for participation in future trials were assessed.
Results: Men were a median 25 years old (inter-quartile range = 23–29), 53% were employed, 90% secondary school
educated and 67% uncircumcised. Of the 900 scheduled study visits, 90% were completed in the immediate
vaccination arm (405/450) and 88% (396/450) in the delayed arm (P = 0.338). Acceptability of trial procedures and
services was very high overall. However, only 65% of the deferred group strongly liked being randomised
compared to 90% in the immediate group (P = 0.001). Informed consent processes were viewed favourably by
92% of the delayed and 82% of the immediate group (P = 0.080). Good quality health services, especially if
provided by a male nurse, were rated highly. Even though almost all participants had some concern about the
safety of a future HIV vaccine (98%), the majority were willing to participate in a future trial. Future trial participation
would be motivated mainly by the potential for accessing an effective vaccine (81%) and altruism (75%), rather than by
reimbursement incentives (2%).
Conclusions: Recruitment and retention of men into vaccine trials is feasible and acceptable in our setting. Findings
from this surrogate vaccine trial show a high willingness to participate in future HIV vaccine trials. While access to
potentially effective vaccines is important, quality health services are an equally compelling incentive for enrolment.
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Background
In 2015, there were 37 million people estimated to be
living with HIV globally; 26 million in sub-Saharan Africa
(SSA), of which 10 million were men [1]. Despite the
scaling up of access to HIV testing, condoms, voluntary
medical male circumcision and antiretroviral treatment
(ART), 2 million new infections occurred in 2015, 68%
in SSA [1–4]. An effective HIV vaccine represents the
best long-term hope for controlling the pandemic [3, 5, 6],
but several features of the virus, including its rapid muta-
tion and multiple clades, pose considerable challenges to
the development of an efficacious vaccine [7, 8]. Despite
this, the RV144 Thai phase III HIV vaccine trial using two
booster injections in addition to a recombinant canarypox
vector vaccine showed a modest reduction in HIV infec-
tions [9]. Further trials of this approach are planned for
Southern Africa, with the aim of extending the RV144 re-
sults and ultimately of vaccine licensure [7, 8].
Conducting large phase III HIV prevention trials is
challenging, however, and relatively little is known about
men’s participation in HIV prevention research [10]. Most
HIV prevention interventions investigated so far have been
targeted at women, who have a higher risk for infection
and a compelling need for female-controlled methods of
HIV prevention [11–13]. In this context, research is usually
focussed only indirectly on men in their role as sexual part-
ners of women, rather than as actual participants in a trial
[14]. Evaluation and licensure of an HIV vaccine will,
however, require the enrolment of large cohorts of men
at risk for HIV infection, given, among other reasons,
that immune responses to vaccines vary by gender [15].
Current evidence for HIV vaccine acceptability and
trial feasibility comes largely from studies focussing on
women [16, 17], people who inject drugs [18], men who
have sex with men [19], discordant couples [16] and
male army conscripts [20–22]. There are clearly evidence
gaps around the feasibility of HIV vaccine trials among het-
erosexual men in SSA. Vaccine preparedness studies that
have explored willingness to participate (WTP) in HIV vac-
cine trials have been conducted without using an actual
vaccine or a clinical trial design [23–25]. Giving an actual
vaccine – even if not an HIV vaccine – would more closely
approximate an HIV vaccine trial, enabling investigation of
trial procedures, such as randomisation, the provision of re-
peated vaccine doses and the monitoring of adverse events.
Using a trial design also allows for assessment of the per-
spectives of men towards being randomised and how that
process is explained during informed consent. Furthermore,
understanding whether trial participation is driven by a de-
sire for access to a vaccine perceived as protective, the clin-
ical attention received as a trial participant, or the trial as a
whole is important. These questions are best answered in
people who have actually participated in a trial, rather than
by eliciting hypothetical views.
Recent experiences of suboptimal adherence to poten-
tially efficacious interventions in HIV prevention trials
have provided a timely reminder about the importance of
including end-user perspectives in the design and delivery
of prevention products [26, 27]. We conducted a pilot ran-
domised controlled trial using a hepatitis B vaccination as
a surrogate for an HIV vaccine in high-risk HIV-negative
men in Johannesburg, South Africa. We evaluated the
recruitment rate, retention, adverse events, behaviour
changes and willingness to participate in future HIV
vaccine trials, and specifically explored whether participa-
tion in a trial would be motivated by access to the vaccine,
or to the clinical care and the trial as a whole.
Methods
Study population
From August to September 2011, participants were re-
cruited from primary health care clinics in Johannesburg
Region F, male-oriented venues in the community and
referrals from enrolled participants. The following clinics
were involved: Esselen, Jeppe Joubert Park, Malvern,
Marshalls Town, Mayfair, Rosettenville and Yeoville clinics,
and the Hillbrow Community Health Centre. Men were
considered eligible for enrolment if older than 18 years,
sexually active (had sex in past 3 months), HIV negative,
negative for hepatitis B core antigen and hepatitis B surface
antigen (chemiluminescent microparticle immunoassay,
Abbott Architect i2000), and if they had no clinical evi-
dence of chronic hepatitis B infection. Men with a history
of bleeding disorders, hypersensitivity to the hepatitis B
vaccine or its ingredients, and those with evidence of acute
infection or a fever >37.8 °C were excluded. Those excluded
for medical conditions were referred to local health care
facilities for further management and care.
Randomisation and study procedures
Eligible participants who demonstrated adequate under-
standing of trial procedures through a comprehension
checklist were enrolled after providing written informed
consent for study participation and for long-term storage
of biological specimens. Informed consent procedures
included a thorough explanation of randomisation
concepts, study visit schedules and encouragement of
participants to discuss any concerns about the study. A
pre-vaccination assessment, including physical and
genital examination, was performed for evidence of
sexually transmitted infections (STIs).
Sequentially numbered envelopes containing study
allocation were pre-prepared by an independent statis-
tician based on simple randomisation using a random
number list. Envelopes were assigned consecutively and
opened in the presence of the participant. Participants
were randomised 1:1 to receive immediate vaccination
(IV) or deferred vaccination (DV). The hepatitis B vaccine
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ENGERIX-B or equivalent generic from the GSK Biologi-
cals was administered in three doses during the study in
the IV group (at enrolment, and at months 1 and 6). Partic-
ipants in the DV group were offered vaccination at the
month 12 visit, again given in three doses. In accordance
with manufacturer’s instructions, 1-mL adult dose was pro-
vided, that contains 20 mcg of hepatitis B surface antigen
adsorbed on 0.5 mg aluminium as aluminium hydroxide.
The adult formulation contained sodium chloride (9 mg/
mL) and phosphate buffers (disodium phosphate dihydrate,
0.98 mg/mL; sodium dihydrogen phosphate dihydrate,
0.71 mg/mL). Vaccination was deferred to the next visit in
those that had evidence of an acute febrile illness.
The hepatitis B vaccine was selected as it shares some
features with a potential HIV vaccine: the infective agent
in both cases is a virus that causes chronic infection and
shares transmission modes, and the hepatitis B’ vaccine’s
multi-dose regimen is likely analogous to that of a future
HIV vaccine. Deferring vaccination, rather than adminis-
tering a placebo vaccine, for example, enabled us to com-
pare the hypothetical perspectives and adverse events
between the groups. Relative rates of adverse events in the
two groups may provide useful information on the ex-
pected rates of vaccine site soreness or swelling in future
HIV vaccine trials, for example. Lastly, providing a vaccine
after study completion may actually occur in HIV vaccine
trials, where participants in a placebo arm may be invited
to receive the HIV vaccine if it were shown to be effective.
Following randomisation, participants were seen at
monthly intervals for the first 3 months of follow-up, and
then quarterly until month 12. A structured interviewer-
administered questionnaire was administered at baseline
and every 3 months thereafter. At screening for study en-
rolment and each quarterly visit, participants were also
counselled and tested for HIV using Determine HIV-1/2
rapid tests (Alere DetermineTM), followed by Unigold
RecombigenTM. Discordant results were confirmed using
Vironostika HIV-1 ELISA testing. Blood samples at
baseline were also tested for syphilis (rapid plasma re-
agin and Treponema pallidum particle agglutination
tests) and HSV-2 (HerpeSelect HSV-2 ELISA IgG; Focus
Diagnostics). Urine samples were tested for N. gonorrhoeae,
C. trachomatis and T. vaginalis using a multiplex PCR
(Seeplex® STI Master Panel 1, 2, 3).
During interviews, data were collected on participants’
socio-demographics, sexual behaviours and medical his-
tory. Post-vaccination assessments for adverse events
were performed 30 min after vaccination and 1 month
thereafter. To allow for comparison of the rates of ad-
verse events between the two study arms, we collected
data on adverse events in all participants at enrolment,
and at months 1, 2, 6, 7. Adverse events at enrolment
were collected 30 min after vaccination in the IV group
and after randomisation in the DV group for comparative
purposes. At all visits, participants received risk-reduction
counselling, free condoms, and STI treatment if required
(syndromic for symptomatic STIs or treatment for asymp-
tomatic curable infections diagnosed with laboratory test-
ing). Those testing positive for HIV during the trial were
retained in the study, and referred to local HIV treatment
facilities for further care.
At month 12, to assess acceptability of participation in
the current trial and in future HIV vaccine trials, we
collected data on participants’ perspectives on several
aspects of the study procedures (10 items) and clinical
services they had received (10 items). In these measures,
participants were asked to rate how they felt about the
procedure or service on a scale of 0–5 (with 0 being those
least liked and 5 being most liked).
Outcome measures and analysis
The primary outcomes were the proportion of men
screened who fulfilled all eligibility criteria and accepted
enrolment; the number of expected visits actually attended;
and the proportion successfully retained in the trial at
12 months. We also calculated the ratio of screened-to-
enrolled men and used Generalised Estimating Equations
to identify factors associated with retention. Model selec-
tion was carried out beginning with the set of significant
univariate predictors (P < 0.1) and model fit assessed using
goodness of fit tests. The variables study group (DV
and IV) and age were forced into the model. In a separ-
ate univariate analysis, we also explored whether any of
the 20 acceptability items were associated with reten-
tion. In this exploratory analysis we defined retention
as having attended all four visits (acceptability was asked
at month 12, so this analysis only included those who had
attended that visit).
Vaccine dose completion and frequency of AEs were
considered additional measures of trial feasibility. In
the IV group, AEs occurring 30 min after vaccine ad-
ministration or up to 1 month later were considered
post-vaccination events. For analysis of acceptability,
we compared the proportion in each study arm who
rated an item as a 4 or 5. WTP was assessed at month
12 by the proportion who said they would join a future
HIV vaccine trial. Participants were also asked if they
would want to receive an HIV vaccine, should it be
shown to be effective, approved and registered. Finally,
we explored the phenomenon of risk compensation by
comparing sexual behaviours in each group (condom
use, alcohol intoxication during sex, number of partners
and having an HIV-positive partner) at quarterly visits.
HIV incidence and the point prevalence of STI episodes
were estimated in the overall cohort. Differences between
categorical variables were examined using the chi-square
test or Fisher’s exact test when the expected values in any
of the cells was below five [28]. Wilcoxon Rank Sum tests
The Author(s) BMC Public Health 2017, 17(Suppl 3):524 Page 115 of 122
were used for comparing continuous data. All analyses
were performed using StataTM Version 12.
Results
Participant characteristics
In total, 284 men were screened and 150 then rando-
mised to receive immediate (n = 75) or deferred (n = 75)
vaccination (screen-to-enrol ratio = 1.89). The main
reasons for non-enrolment were positive hepatitis B
serology or HIV infection (Fig. 1). Compared to those
enrolled, non-enrolled men were older, more likely to
be married, and reported lower rates of condom use
and more lifetime partners (Table 1). A quarter of non-
enrolled men perceived themselves to be at high-risk
for HIV, consistent with the prevalence of HIV (12%),
reactive syphilis serology (12%) and HSV-2 (41%) in
these men. C. trachomatis infection rates were high in
both study arms and the non-enrolled men (6.7–9.0%).
Baseline characteristics of participants in the two trial
arms were similar (Table 1). Enrolled participants were a
median 25 years (inter-quartile range [IQR] = 23–29). The
majority were single (85%), secondary school educated
(90%), employed (53%) and resident in Johannesburg for
more than a year (91%). Median age at sexual debut was
16 years (IQR = 15–19) and men had a median 8 lifetime
partners (IQR = 5–15). High baseline condom use (70%)
and low levels of circumcision (33%) characterised this
population. HSV-2 prevalence was 24% in the enrolled
participants.
Feasibility and study retention
Overall, 801/900 (89%) of the expected visits were com-
pleted (405/450 [90%] IV vs. 396/450 [88%] DV, P = 0.338;
Fig. 1). Median follow-up time was 11.8 months in both
groups. Seven in the IV group and 9 in the DV group did
not attend the month 12 visit, despite repeated attempts
to trace them (2 in IV and 3 in DV could not be con-
tacted). Other reasons for participant loss included travel
away from the area (IV = 1 vs. DV = 2), relocation (IV = 1
vs. DV = 2), inability to attend due to work or school com-
mitments (IV = 2 vs. DV = 1) and incarceration (IV = 1 vs.
DV = 1). In multivariate analysis (Additional file 1: Table
Fig. 1 CONSORT Diagram – Flow of participants through trial period
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S1), no difference was detected between retention in the
two study arms (adjusted OR comparing DV to IV = 1.36;
95% CI = 0.56–3.35). The odds of retention in men who
had an adverse event were 3.76 that of other men (95% CI
adjusted OR = 0.82–17.14). Age was not associated with
retention.
Vaccine completion
In the IV group, no participants refused vaccination
post-enrolment, but 5% missed dose 2 (4/75) and 8%
dose 3 (6/75). Two had vaccinations deferred until the
next visit, one with a contra-indication (flu) and one
who missed the scheduled visit. Dose completion in the
IV group was more frequent in men reporting consistent
than inconsistent condom use in the 3 months prior to
baseline (94% vs. 75%, P = 0.022), and in those who had
lived in Johannesburg for over a year, compared to
briefer periods (93% vs. 67%, P = 0.006).
At study end, 61% (40/66) of participants in the DV
group returned for hepatitis B vaccination. Reasons
given for non-acceptance included unwillingness to be
vaccinated (6) and current receipt of TB treatment (1).
No differences were noted in the sociodemographic
characteristics or acceptability measures between those
in the DV group who were or were not vaccinated.
Overall, 61 AEs were reported. All AEs were non severe
(Grade 1) and no allergic reactions related to vaccination
were reported. More AE were reported by the IV than DV
study arm (40 versus 21, p ≤ 0.001; Table 2). Much of this
difference is accounted for by injection site soreness or
swelling in the IV group (12). In the IV group, 17% re-
ported an AE after the month 1 vaccine and 13% after the
month 6 vaccine.
Five HIV infections (1 in IV and 4 in DV group) were
observed over the 1598.3 person-months of follow up (HIV
incidence 0.3/100 person months; 95% CI: 0.2–0.9). No in-
cident cases of hepatitis occurred during the trial. All five
infections occurred in the first 6 months of follow-up.
Changes in risk behaviour
In both study groups, men reported a higher coital fre-
quency and lower condom use at baseline than at all
Table 1 Baseline characteristics of men, comparison by enrolment status and study arm
Variable Enrolled Not enrolled
(C) (n = 134)
P
(A + B vs C)Immediate
(A) (n = 75)
Deferred
(B) (n = 75)
P
(A vs B)
Median age (IQR) 25 (23–29) 26 (23–29) 0.390 30 (26–36) <0.001
Born in SA 50 (66.7) 49 (65.3) 0.864 93 (69.4) 0.541
Single 64 (85.3) 64 (85.3) 1.000 102 (76.1) 0.002
Any employmenta 40 (53.3) 40 (53.3) 1.000 78 (58.2) 0.409
Completed secondary education 72 (96.0) 63 (84.0) 0.018 115 (85.8) 0.482
Johannesburg resident >1 year 69 (92.0) 67 (89.3) 0.575 120 (89.6) 0.530
Median lifetime partners (IQR) 7 (5–13) 9 (5–20) 0.238 10 (6–20) 0.007
Median age coital debut (IQR) 16 (15–18) 16 (15–19) 0.861 17 (15–19) 0.132
Used condom at each sex actb 47 (62.7) 58 (77.3) 0.063 45 (52.3) 0.052
High-risk female partnersc 33 (44.0) 31 (41.3) 0.741 62 (51.7) 0.767
Vaccination historyd 48 (64.0) 55 (73.3) 0.309 106 (79.1) 0.126
Perceived HIV risk 10 (13.3) 6 (8.0) 0.551 32 (23.9) 0.010
Previous sex with male partner 2 (2.7) 1 (1.3) 0.500 4 (3.0) 0.710
Circumcised 22 (29.3) 27 (36.0) 0.384 48 (35.8) 0.545
Syphilise 2 (2.7) 2 (2.7) 0.690 16 (11.9) <0.001
N. gonorrhoeae 2 (2.7) 1 (1.3) 0.500 2 (1.5) 0.553
T. vaginalise 1 (1.3) 0 (0.0) - 6 (4.5) 0.055
C. trachomatis 10 (6.7) 12 (8.0) 0.907 12 (9.0) 0.139
HSV-2 17 (22.7) 19 (25.3) 0.512 54 (41.2) <0.001
HIV-1 0 (0.0) 0 (0.0) - 16 (12.0) -
Hepatitis B 0 (0.0) 0 (0.0) - 87 (65) -
HIV and hepatitis co-infection 0 (0.0) 0 (0.0) - 10 (7) -
aPart-time, self- or full-employment; bIn past 3 months, with most recent partner; cSex partner has other partners and never tested for HIV to man’s knowledge;
dAny vaccination, including experimental or immunisations. eFisher’s exact test
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subsequent visits (Table 3). Compared to the IV group,
a higher proportion of DV participants reported sex
with a condom at each study visit, including at enrol-
ment. The DV group also had more alcohol-intoxicated
sexual acts at each visit than the IV group. However,
neither condom use nor intoxication differences were
significant. Few men reported having sex with a partner
known to be HIV positive at enrolment, and levels were
even lower at subsequent visits (P = 0.061). At study
end, participants rated the validity of their responses to
Table 2 Frequency of adverse events at enrolment, and months 1, 2, 6 and 7, by study arm (total visits = 600)
Type of event Enrolment
(n = 150) n events (%)
Month 1 (pre-vaccination),
2 (post-vaccination)
(n = 141) n events (%)
Month 6 (pre- vaccination),
7 (post- vaccination)




IV (n = 75) DV (n = 75) IV (n = 71) DV (n = 70) IV (n = 71) DV (n = 68)
Pre Post ‘Pre’ ‘Post’ Pre Post ‘Pre’ ‘Post’
Chills 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.7) 3 (4.1) 2 (2.7) 1 (1.3) 1 (1.4) 1 (1.4) 10 (0.7)
Headache 0 (0.0) 2 (2.7) 1 (1.3) 3 (4.0) 3 (4.1) 0 (0.0) 3 (4.0) 0 (0.0) 0 (0.0) 1 (1.4) 13 (1.0)
Nausea 2 (2.7) 1 (1.4) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0) 0 (0.0) 5 (0.4)
Fatigue 0 (0.0) 0 (0.0) 1 (1.3) 1 (1.3) 1 (1.4) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0) 0 (0.0) 5 (0.4)
Limited ADLc 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0) 2 (0.2)
Dizziness 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.3) 2 (2.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.2)
Injection site soreness 0 (0.0) 0 (0.0) 1 (1.3) 3 (4.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (8.0) 0 (0.0) 0 (0.0) 10 (0.7)
Injection site swelling 0 (0.0) 0 (0.0) 1 (1.3) 1 (1.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.2)
Allergic reaction 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Otherb 5 (6.7) 4 (5.4) 0 (0.0) 2 (2.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0) 0 (0.0) 11 (0.8)
Total 7 (9.3) 7 (9.3) 5 (7.0) 12 (16.9) 8 (11.4) 3 (4.3) 7 (9.9) 9 (12.7) 1 (1.5) 2 (2.9) 61 (10.2)a
aAEs collected at total of 600 visits; Post-vaccination events in IV arm include events 30 mins or 1 month after vaccination; DV arm ‘pre’ AEs are those recorded at
time of visit, and ‘post’ are AEs at visit 1 month later.bOther reported AEs include: cough, nights sweats and tonsillitis; cActivities of daily living. Fisher’s exact test
done to compare groups, all P values were >0












Median sexual partners in past 3 months IV 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 0.993
DV 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2)
P* 0.769 0.644 0.685 0.959 0.558
Median sexual acts in past 3 months IV 9 (3–21) 6 (2–12) 5.5 (2–12) 5 (2–10) 6 (3–15) -
DV 9 (3–20) 6 (3–14) 6 (3–11) 6 (3–11) 6 (3–12)
P* 0.795 0.339 0.392 0.489 0.972
Condom use in past 3 months IV 55 (73.3%) 56 (81.1%) 55 (80.9%) 50 (79.4%) 52 (81.3%) 0.461
DV 62 (82.7%) 60 (87.0%) 57 (85.1%) 58 (86.6%) 55 (84.6%)
P* 0.168 0.352 0.517 0.274 0.611
HIV-positive sex-partnera, c IV 2 (2.7%) 0 (0.0%) 0 (0.0%) 0 (0%) 0 (0.0%) 0.061
DV 3 (4.0%) 1 (1.3%) 2 (2.7%) 1 (1.3%) 2 (2.7%)
P* 0.500 0.500 0.248 0.500 0.248
Sexual acts while intoxicated in past 3 months IV 12 (16.0%) 16 (21.3%) 13 (17.3%) 17 (22.7%) 18 (24.0%) 0.233
DV 18 (24.0%) 19 (25.3%) 18 (24.0%) 20 (26.7%) 19 (25.3%)
P* 0.221 0.562 0.313 0.570 0.850
Incident HIV infectionb, c IV - 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.299
DV - 2 (2.7%) 1 (1.4%) 0 (0.0%) 0 (0.0%)
P* - 0.245 0.497 - -
aWhere participant knows partner’s HIV status; *P value compares groups at every month; #P value across visits overall; b2 incident HIV infections at Month 2 in IV
group; cFisher’s exact test
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self-reported questions, scoring themselves relatively
high with condom use (IV 60 [88%] vs. DV 56 [85%]),
number of partners (IV 65 [96%] vs. DV 58 [88%]) and
sexual behaviour in general (IV 67 [89%] vs. DV 65
[98%]).
Acceptability
Of the study procedures assessed, more than 90% of par-
ticipants rated questionnaire completion, repeated HIV
testing and receipt of reimbursements as a 4 or 5 out of
5 (Table 4). Only 65% of the deferred group, however,
gave high ratings for being randomised, compared to
90% of the immediate group (P = 0.001). By contrast,
92% of the DV group held favourable views on the in-
formed consent processes, compared to 82% of the IV
group (P = 0.080). The collection of blood and genital
specimens were viewed relatively unfavourably by both
groups.
In terms of the clinical services and visits, in both
groups, being examined by a male nurse was viewed as
more acceptable than a female one. All men in the IV
group liked being examined by a male nurse, while these
views were not universal among men in the DV group
(96%; P = 0.075). Other highly preferred aspects of the
clinical services in both groups (>90% participants
scored item as 4 or 5) were: clean clinic environment,
clinic staff attitudes, free treatment and condoms, and
counselling and health information, and the hepatitis B
vaccine itself. Only 79% of the IV and 83% of the DV
group scored travel time favourably (P = 0.560).
No associations were detected between the acceptability
items and having attended all four study visits (Additional
file 2: Table S2). Attendance levels among those who held
less favourable views on the clinical services were high.
Though differences were not significant, on 8 of the 10
measures of clinical services, those with less favourable
views had a higher attendance than those with more
favourable perceptions.
WTP in a future HIV vaccine trial was high in both
groups (64/68, 94% in IV vs. 62/63, 98% in DV; P = 0.200).
The main motivations for participation were potential
HIV protection (81%), to help find a vaccine that works
(75%), and to help others (68%). Interestingly, only 2%
reported that reimbursements for study visits would
motivate participation. Free HIV testing and treatment,
and knowing someone with HIV were also not regarded
as incentives for participation. No variations by study
group were observed in these views. Almost all viewed
side effects as a major concern for future trial partici-
pation (98%).
When asked about future use of an effective HIV
vaccine, essentially all reported that they would accept
this vaccine for themselves or their children. The most
important attribute favouring vaccine acceptance was
durability of protection (93/131, 70%). Few viewed ease of
access (20/131, 15%), side effects (12/131, 9%), cost (3/
131, 2%), number of doses (0/131, 0%) and duration that
the vaccine was on the market (3/131, 2%) as important
factors influencing whether they would accept an HIV vac-
cine known to be effective. Again, findings were similar
between the two study arms.
Discussion
This study indicates that it is feasible to recruit and re-
tain a population of high-risk heterosexual men in an
HIV vaccine trial in Johannesburg, South Africa. Recruit-
ment was relatively efficient, with a screen-to-enrol ratio
under two. Compared to non-eligible men, however,
those enrolled in the study had lower risk behaviours
and consequently are likely to have fewer incident HIV
Table 4 The proportion of participants at month 12 who felt
they liked the study procedures and clinical services, by study
arm (n = 134)
Item Immediate
vaccination
(n = 68) n liked
or very liked (%)
Deferred
vaccination
(n = 66) n liked
or very liked (%)
P
Study procedures
Informed consent 56 (82.4) 61 (92.4) 0.080
Randomisation 61 (89.7) 43 (65.2) 0.001
Completing questionnaires 62 (92.5) 61 (92.4) 0.980
Physical examination 60 (88.2) 56 (84.9) 0.565
Genital examination 59 (86.8) 55 (83.3) 0.436
Collection of blood samples 58 (85.3) 58 (87.9) 0.661
Repeated HIV testing 68 (100.0) 63 (95.5) 0.075
Collection of genital samples 59 (86.8) 58 (87.9) 0.846
Reimbursement 64 (94.1) 65 (98.5) 0.182
Other study activitiesa 53 (91.4) 52 (91.2) 0.977
Clinical services
Visit schedules 64 (86.4) 57 (94.1) 0.129
Travel time to clinic 54 (79.4) 55 (83.3) 0.560
Clean clinic environment 68 (100.0) 65 (98.5) 0.308
Waiting time at clinic 67 (98.5) 62 (93.9) 0.161
Clinic staff attitude 68 (100.0) 65 (98.5) 0.308
Examination by female
nurse
48 (70.6) 51 (77.3) 0.379
Examination by male nurse 68 (100.0) 63 (95.5) 0.075
Free treatment and
condoms
67 (98.5) 64 (97.0) 0.542
Free counselling, health
information
68 (100.0) 64 (98.5) 0.305
Hepatitis B vaccinationb 61 (91.0) - -
aOther activities included in-depth interviews, focus group discussions and
home visits’; bonly for those who received the surrogate vaccine; †chi-square
test used to calculate P value
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infections. This phenomenon raises the sample size re-
quired for demonstrating efficacy of an intervention
[29]. Follow-up rates, approximately equal in both arms,
were higher than in many previous vaccine preparedness
studies among men [22].
In both study arms, the levels of WTP in an HIV trial
were among the highest recorded among men in similar
studies to date. In a review of 16 preparedness studies
[22], willingness ranged from 40–99.4%, and was lower
among men than women in most [22, 24, 30], but not all
studies [31]. More generally, men are often less engaged
in health care than women – which is commonly attributed
to gendered social behaviours, occupational obligations and
even a disinterest in their own health [32, 33] – and this
may influence their decision to participate in trials. It was
thus noteworthy to observe that the study population were
highly motivated to enrol in future trials. Similar to other
studies, altruistic motives often underlined this WTP,
expressed as a desire to help find an efficacious vaccine and
thereby contribute to improving the health of others and
the greater community [10, 20, 21, 24, 25, 34, 35]. Though
men looked very favourably upon reimbursements, they
said that these would not motivate them to join a trial. This
contrasts with commonly held views and some evidence in
other studies in SSA that monetary incentives raise partici-
pation [36, 37].
Use of a surrogate vaccine and randomisation into
immediate and deferred vaccine groups provided useful
insights. Most especially, we were able to evaluate the
relative acceptability of the different components of a
future vaccine trial. The levels of discontent about the
informed consent procedures in the IV arm suggest that
participants require more information during consent re-
lating to the vaccine and study procedures. Consent also
needs to focus on ensuring participants comprehend the
concepts of randomisation and unknown efficacy to avoid
therapeutic misconception and potential increases in risk
behaviours.
Also, in this study, as in others [21, 25], participants
raised concerns about randomisation, particularly to a
control or placebo group. Further, it is evident that many
attributes of a study clinic, such as cleanliness and clinic
staff attitudes, were highly valued by participants and
likely are key determinants of retention in future trials.
Notably, men placed a high premium on examination
by a male health worker. The study design allowed us
to demonstrate low return rates in the DV group for
vaccination at month 12 when the vaccine was to be
given to this group. This may have been because financial
reimbursements and other clinical services were not
provided at these visits. The latter two factors are per-
haps more important than access to a technology, such
as a vaccine, per se. While seemingly not a major bar-
rier to participation, collection of specimens and travel
distance to study clinics were important considerations
for participants.
Even though men in the IV group experienced higher
rates of adverse events than those allocated to DV, cohort
retention was similar between study arms. While these
events were all minor, this finding seemingly contrasts
with that of a systematic review of qualitative studies on
participation in HIV vaccine trials [38]. That review noted
that vaccine safety was a foremost concern among poten-
tial trial participants (as in our study), but that this might
undermine retention. Quite plausibly, however, patients
who are concerned about adverse events might actually at-
tend study visits to seek reassurance about their health,
and therefore have high retention, as in this study.
A potential concern for all randomised blinded pla-
cebo controlled trials of HIV preventive technologies is
the possibility that participants believe themselves to be
protected against HIV, despite the vaccine’s unknown ef-
ficacy and the possibility that they were randomised to
the placebo arm [16, 18]. In fact, many of the men in
this study cited the potential for a vaccine to protect
themselves from HIV infection as the principal motivator
for joining a trial. In an HIV vaccine trial in Thailand,
young recruits reduced condom use as their perception of
HIV risk was lowered due to the vaccine [20]. By contrast,
as in many other HIV prevention studies [3, 17, 19, 20,
35], risk activity actually decreased early on in our study in
both groups. Overall, given the reduction in risk behav-
iours over time and fewer number of HIV infections in the
IV group, this study does not support concerns about ad-
verse changes in risk behaviour within HIV vaccine trials
[39]. Nonetheless, counselling for participants in HIV tri-
als in this setting should strongly address misconceptions
about the efficacy of the candidate product [19, 20].
Overall, we contend that the use of randomisation, an
actual vaccine and an untreated control group extends
to knowledge beyond previous hypothetical vaccine
studies. However, though the study findings might help
optimise the design of future HIV vaccine trials, recruit-
ment and retention rates in this study may not necessar-
ily reflect those of a future trial. Firstly, the hepatitis B
vaccine is of proven efficacy and hepatitis B differs from
HIV in many important ways. Moreover, self report of
WTP does not necessarily translate into participation in
an HIV vaccine trial [10, 22, 24]. Other study limitations
also bear mention. The small sample size constrained
our ability to explore differences between groups, pre-
dictors of WTP and acceptability. Further, the majority
of the risk behaviour responses were self-reported and
influenced by social desirability and other biases. Partici-
pants, however, rated their responses as mostly truthful
and we were able to triangulate their behavioural re-
sponses with HIV incidence, an objective marker of
ongoing risk.
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Conclusions
Despite its limitations, the study was able to demonstrate
a high degree of WTP in future trials, as shown by the
actual retention rates and views expressed on the issue.
Recruitment of men into vaccine trials that address the
concerns raised here is therefore likely to be feasible and
acceptable in this setting. While access to vaccines was an
important motivation for enrolment in a future trial, qual-
ity health services were viewed as equally important, espe-
cially those provided by a male health worker. Moreover,
the differences noted between study groups in sexual be-
haviour shows that changes in sexual behaviours might be
anticipated in a vaccine trial in this population. Lastly, use
of a surrogate vaccine, unlike previous studies based on
hypothetical acceptability [22, 24, 40], replicates actual
vaccine trial procedures and may enhance the ability of
participants to accurately assess the perceived benefits and
realistic consequences of participation.
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